Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
Nurix Therapeutics (Nasdaq: NRIX) announced upcoming presentations of preclinical data at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, held November 14-19, 2024, in Washington, D.C. The presentations will focus on two of Nurix's drug candidates:
1. NX-5948: A BTK degrader in Phase 1b development for B-cell malignancies and IND-enabling studies for autoimmune diseases. The poster will showcase its efficacy in suppressing BCR, TLR, and FcR signaling in immune cells and its performance in preclinical models of arthritis and other inflammatory diseases.
2. GS-6791/NX-0479: An IRAK4 degrader developed in collaboration with Gilead Sciences, currently in IND-enabling studies. The presentation will demonstrate its ability to inhibit TLR and IL-1R-driven inflammatory signaling and its effects in a preclinical arthritis model.
Nurix Therapeutics (Nasdaq: NRIX) ha annunciato le prossime presentazioni di dati preclinici al ACR Convergence 2024, il meeting annuale del College Americano di Reumatologia, che si svolgerà dal 14 al 19 novembre 2024 a Washington, D.C. Le presentazioni si concentreranno su due dei candidati farmaceutici di Nurix:
1. NX-5948: Un degrader di BTK in fase di sviluppo 1b per le neoplasie a cellule B e studi abilitanti per la richiesta di indagine (IND) per malattie autoimmuni. Il poster metterà in evidenza la sua efficacia nel sopprimere il segnale di BCR, TLR e FcR nelle cellule immunitarie e la sua performance in modelli preclinici di artrite e altre malattie infiammatorie.
2. GS-6791/NX-0479: Un degrader di IRAK4 sviluppato in collaborazione con Gilead Sciences, attualmente in studi abilitanti per IND. La presentazione dimostrerà la sua capacità di inibire il segnale infiammatorio indotto da TLR e IL-1R e i suoi effetti in un modello preclinico di artrite.
Nurix Therapeutics (Nasdaq: NRIX) anunció las próximas presentaciones de datos preclínicos en el ACR Convergence 2024, la reunión anual del Colegio Americano de Reumatología, que se llevará a cabo del 14 al 19 de noviembre de 2024 en Washington, D.C. Las presentaciones se centrarán en dos de los candidatos a fármacos de Nurix:
1. NX-5948: Un degradador de BTK en desarrollo de fase 1b para malignidades de células B y estudios habilitantes para enfermedades autoinmunes. El cartel destacará su eficacia en suprimir la señalización de BCR, TLR y FcR en células inmunitarias y su rendimiento en modelos preclínicos de artritis y otras enfermedades inflamatorias.
2. GS-6791/NX-0479: Un degradador de IRAK4 desarrollado en colaboración con Gilead Sciences, actualmente en estudios habilitantes para IND. La presentación demostrará su capacidad para inhibir la señalización inflamatoria impulsada por TLR y IL-1R, así como sus efectos en un modelo preclínico de artritis.
누릭스 테라퓨틱스(Nasdaq: NRIX)는 2024년 11월 14일부터 19일까지 워싱턴 D.C.에서 열리는 미국 류마티스학회(ACR)의 연례 회의에서 발표할 예정인 전임상 데이터에 대한 발표를 발표했습니다. 발표는 누릭스의 두 약물 후보에 집중할 것입니다:
1. NX-5948: B세포 악성종양을 위한 1b 단계 개발 중인 BTK 분해제이며 자가면역질환을 위한 IND 허가 연구 중입니다. 포스터는 면역 세포에서 BCR, TLR 및 FcR 신호를 억제하는 효능과 관절염 및 기타 염증 질환의 전임상 모델에서의 성과를 보여줄 것입니다.
2. GS-6791/NX-0479: Gilead Sciences와 협력하여 개발된 IRAK4 분해제로, 현재 IND 허가 연구 중입니다. 발표는 TLR 및 IL-1R에 의해 유도된 염증 신호를 억제하는 능력과 전임상 관절염 모델에서의 효과를 보여줄 것입니다.
Nurix Therapeutics (Nasdaq: NRIX) a annoncé les prochaines présentations de données précliniques lors de ACR Convergence 2024, la réunion annuelle du Collège Américain de Rhumatologie, qui se tiendra du 14 au 19 novembre 2024 à Washington, D.C. Les présentations porteront sur deux des candidats médicaments de Nurix :
1. NX-5948 : Un dégradateur de BTK en développement en phase 1b pour les malignités des cellules B et les études permettant de demander une autorisation d'investigation (IND) pour les maladies auto-immunes. L'affiche mettra en avant son efficacité à supprimer la signalisation BCR, TLR et FcR dans les cellules immunitaires et ses performances dans des modèles précliniques d'arthrite et d'autres maladies inflammatoires.
2. GS-6791/NX-0479 : Un dégradateur de l'IRAK4 développé en collaboration avec Gilead Sciences, actuellement en études permettant de demander une autorisation d'investigation. La présentation démontrera sa capacité à inhiber la signalisation inflammatoire induite par TLR et IL-1R ainsi que ses effets dans un modèle préclinique d'arthrite.
Nurix Therapeutics (Nasdaq: NRIX) hat die bevorstehenden Präsentationen von präklinischen Daten auf der ACR Convergence 2024, der Jahresversammlung des American College of Rheumatology, angekündigt, die vom 14. bis 19. November 2024 in Washington, D.C. stattfindet. Die Präsentationen werden sich auf zwei der Arzneimittelkandidaten von Nurix konzentrieren:
1. NX-5948: Ein BTK-Degrader in der Phase 1b Entwicklung für B-Zell-Malignitäten und IND-erlaubende Studien für Autoimmunerkrankungen. Das Poster wird seine Wirksamkeit bei der Unterdrückung von BCR-, TLR- und FcR-Signalen in Immunzellen und seine Leistungsfähigkeit in präklinischen Modellen von Arthritis und anderen entzündlichen Erkrankungen präsentieren.
2. GS-6791/NX-0479: Ein IRAK4-Degrader, der in Zusammenarbeit mit Gilead Sciences entwickelt wurde und sich derzeit in IND-erlaubenden Studien befindet. Die Präsentation wird seine Fähigkeit demonstrieren, entzündliche Signale, die auf TLR und IL-1R basieren, zu hemmen, sowie seine Effekte in einem präklinischen Arthritismodell.
- Nurix Therapeutics has two drug candidates progressing in development: NX-5948 in Phase 1b and GS-6791/NX-0479 in IND-enabling studies
- Preclinical data for both drug candidates show promising results in arthritis and inflammatory disease models
- Collaboration with Gilead Sciences on the development of GS-6791/NX-0479 indicates industry interest in Nurix's technology
- None.
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that preclinical data will be presented from NX-5948, Nurix’s proprietary BTK degrader currently in Phase 1b development for B-cell malignancies and in IND enabling studies for autoimmune disease, and GS-6791/NX-0479, an IRAK4 degrader discovered in collaboration with Gilead Sciences and also in IND-enabling studies, in two posters at ACR Convergence 2024, the annual meeting of the American College of Rheumatology (ACR), being held November 14–19, 2024, in Washington, D.C.
Poster Presentation Details:
Title: NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Presenting author: Mark Noviski, Ph.D. (Nurix Therapeutics, Inc.)
Session: B Cell Biology & Targets in Autoimmune & Inflammatory Disease
Session date and time: Saturday, November 16, 2024, 10:30 AM - 12:30 PM
Abstract ID: 1857761
Title: IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Presenting authors: Grace Teng, Ph.D. (Gilead Sciences, Inc.)
Session: Innate Immunity
Session date and time: Sunday, November 17, 2024, 10:30 AM - 12:30 PM
Abstract ID: 1861825
Abstracts are available online at: acrabstracts.org
About NX-5948: NX-5948 is an investigational, orally bioavailable degrader of BTK that is currently being evaluated in a Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies. Additional information on the Phase 1a/b clinical trial can be accessed at www.clinicaltrials.gov (NCT05131022).
About GS-6791 (previously NX-0479): GS-6791 is a potent, selective, oral IRAK4 degrader. Degradation of IRAK4 by GS-6791 has potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix’s collaborator, Gilead Sciences, is responsible for conducting IND-enabling studies and advancing this program to clinical development.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the planned timing for the provision of updates and findings from preclinical studies, including Nurix’s intention to present preclinical data from NX-5948 and GS-6791/NX-0479 at ACR Convergence 2024, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended May 31, 2024, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What drug candidates will Nurix Therapeutics (NRIX) present at ACR Convergence 2024?
What is the current development stage of NX-5948 by Nurix Therapeutics (NRIX)?
When and where will ACR Convergence 2024 be held?
What are the potential applications of GS-6791/NX-0479 being developed by Nurix Therapeutics (NRIX) and Gilead Sciences?
